Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
about
Statins for the primary prevention of cardiovascular diseaseStimulating endogenous cardiac repairBenefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesA point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive CardiologyPatient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility.Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling studyAccumulation of cardiovascular and diabetes medication among apparently healthy statin initiatorsTime trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care dataUsing the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysisThe effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.Update on guidelines for management of hypercholesterolemia.Statins: Can we advocate them for primary prevention of heart disease?When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA).The causal exposure model of vascular diseaseUsing stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.Quality of Diabetes Care in Germany Improved from 2000 to 2007 to 2014, but Improvements Diminished since 2007. Evidence from the Population-Based KORA Studies.Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis.Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular DiseaseA Risk Model and Cost Analysis of Incisional Hernia After Elective, Abdominal Surgery Based Upon 12,373 Cases: The Case for Targeted Prophylactic InterventionChoosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions.Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy ModelAssessment of Coronary Artery Calcium Scoring for Statin Treatment Strategy according to ACC/AHA Guidelines in Asymptomatic Korean Adults.More americans living longer with cardiovascular disease will increase costs while lowering quality of life.Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative cliniciansWho needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelinesOptimal lipid targets for the new era of cardiovascular prevention.A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention.Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines.Impact of statins in outcomes of septic patients: a systematic review.Has cost inhibited the uptake of more potent statins in England?Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea.Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012.ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.
P2860
Q24201513-337631BB-82F8-40F8-8EC2-740E0521FB7AQ26781323-20E05494-7E21-4A3F-BD79-EE143C9075A5Q26853571-2E048059-D795-485A-AE77-86F9911C8E48Q26866033-A3596704-5769-43AB-A553-6072E69CB79EQ27339134-7C976ADA-F028-4348-9564-81B94946E5EBQ28484624-92453940-D11A-4FAB-BF8D-1E02D810B9A2Q28543231-25A4083F-3A36-45B7-911A-6D88E5302F0CQ31108693-3603F7EF-88A8-4AEE-8654-A3615F3E5F60Q34143079-24FBCFFB-02F9-45AD-8E07-3E2C152B6A85Q34274829-C23F35E0-D220-4ABD-9C75-7928C232E856Q34314183-4EA0D25A-A465-4BEE-A679-E91C2F9E9D32Q34425102-4FA18948-AFCF-48C3-AD52-000E07A618C2Q34828582-B26ED717-3AD4-4D92-8CCD-7A54CCA29053Q35191897-FF73B4E5-EF4B-4015-B341-8E5117754327Q35628302-0F9C896B-4C4B-4F20-B1FD-E4E2F2FA3A6AQ35694196-58727741-F769-4AF1-A3E5-1D8CC6DFE02CQ35766202-6D0FB019-C970-413C-8A72-DA8D3A6653D7Q36013827-3AE3B88A-FCA3-4D32-88D1-A86597896511Q36165379-2E08FBA9-D982-4882-8ED2-4E897AF1A4DCQ36215110-4A333C61-1105-498D-BA06-C1C26A05642EQ36247530-BD3BF5B1-A069-4035-ABD5-C62A74E3B0C0Q36701872-2C5057F3-8079-495A-808C-C8C5A1CAD8FEQ36779099-96D9F729-7600-40DD-A60D-5A045D12A778Q36871294-981C6ED8-4B13-4BB4-A63F-C34F15903750Q36973367-A07A8700-7E23-4A12-A574-38585CF7134FQ37265528-28F0D933-6480-43F5-A7D3-A1EE6E6D98C1Q37438420-639057B5-45B8-448E-9562-20150DB2D146Q37489669-7AB045A3-AD32-409E-A760-F2CC54A2C3E5Q37533850-87870020-E70C-427D-9DAD-BB4AC24DF00CQ37677821-59C36405-F1FC-44DC-8D07-A3AC3C429BFEQ38006740-2C73B2E3-0C88-40E9-B595-C04C8292C362Q38044398-3DA958FB-73C9-4E4B-B830-606D6BA1D04CQ38204182-A2098F84-1B01-499E-9B8C-FD43EE39C25BQ38232858-58FF684F-0D02-483A-99B2-C0DAB66653E4Q38267132-B115FF86-9A73-4F5F-BE2F-2BFE6685A6C8Q38726224-C0A0FCFF-11CB-47C6-BF47-6F5871B0BC1CQ38793913-62B45E22-FC84-4775-98F6-41CBE73E3930Q38934196-F60C25C1-406C-4114-AD5E-D6A956A35F51Q39507722-ABE9E03F-2977-4692-ADCA-B4E4EC70F0BFQ40104818-A141234E-CA7A-440C-A626-46633BD491CD
P2860
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
@en
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
@nl
type
label
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
@en
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
@nl
prefLabel
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
@en
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
@nl
P2093
P1433
P1476
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
@en
P2093
Lawrence D Lazar
Lee Goldman
Mark J Pletcher
Pamela G Coxson
P304
P356
10.1161/CIRCULATIONAHA.110.986349
P407
P577
2011-06-27T00:00:00Z